Kornimate/medical-research-clean huggingface dataset:
effects of confortable environment, kangaroo care and music therapy in newborns in neonatal intensive care unit

Conditions: Premature Infant Disease; Newborn Morbidity

Summary: creating a comfortable environment, implementing kangaroo care, and incorporating music therapy are crucial interventions for newborns hospitalized in the neonatal intensive care unit (nicu). these strategies not only contribute to the physical well-being of the infants but also play a significant role in promoting their emotional and developmental health.

the well-being of newborns in the neonatal intensive care unit (nicu) is paramount, and establishing a comfortable environment is a fundamental aspect of their care. this involves controlling factors such as temperature, lighting, and noise to mimic the conditions of the womb, creating a soothing and supportive atmosphere for their fragile development. a calm environment is essential for premature infants, as it can contribute to improved weight gain, better sleep patterns, and overall physiological stability. kangaroo care, a practice involving skin-to-skin contact between the infant and a caregiver, has proven to be a transformative intervention in nicu settings. this method not only fosters the bond between the baby and their parent but also offers numerous physiological benefits. kangaroo care has been associated with stabilized heart and respiratory rates, enhanced weight gain, and improved neurodevelopmental outcomes. the close physical contact provides a sense of security and comfort, mimicking the warmth and safety of the mother's womb. incorporating music therapy into the care routine of nicu infants has demonstrated positive effects on their well-being. music has the power to reduce stress, stabilize vital signs, and promote better sleep patterns. live or recorded lullabies, specifically designed for preterm infants, have been shown to have a calming influence and aid in the regulation of physiological functions. additionally, music therapy can serve as a valuable tool for parents, offering a means of bonding with their hospitalized newborns and alleviating the stress associated with the nicu experience. in conclusion, the utility of a comfortable environment, kangaroo care, and music therapy for newborns in the nicu extends beyond basic medical care. these interventions recognize the holistic needs of premature or ill infants, addressing both their physical and emotional requirements. by prioritizing a nurturing and supportive environment, healthcare providers aim to optimize the developmental trajectory of these vulnerable newborns, fostering better outcomes for their long-term health and well-being.

Eligibility criteria:
inclusion criteria: * newborn hospitalized in nicu exclusion criteria: * not hospitalized in nicu, * intubated infants, * instable clinical condition

Keywords: newborn kangaroo-mother care method music therapy intensive care units, neonatal
efficacy of the apollo system for children with adhd

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: to determine the extent to which the apollo system is effective in reducing symptomatology associated with adhd.

the objective of this project is to understand the potential therapeutic benefits of the apollo system for children with adhd. using vibrational therapy, the apollo system has been previously demonstrated to promote greater balance of the autonomic nervous system. given the importance of the autonomic nervous system for modulating levels of physiological arousal and in-turn governing aspects of attention and self-regulation; a therapeutic approach to promote better balance of this system may be particularly beneficial for populations such as children with adhd. accordingly, using a double-blind randomized placebo-controlled design this investigation will assess the extent to which the apollo system is effective in reducing symptomatology associated with adhd.

Eligibility criteria:
inclusion criteria: all individuals that agreed to participate will be selected on a first come, first serve basis. no individual will be turned down due to sex, race, or ethnicity. the following inclusion criteria exist for all participants: 1. participants must be 8 years of age or older and under the age of 18. 2. participants must have diagnosed or suspected attention deficit hyperactivity disorder (adhd). 3. participants must have one of the following: 1) on the same treatment plan for over a year with minimal symptom relieve or alleviation, 2) tried two or more treatment approaches but is unable to meet treatment goals, 3) taking medication but still has symptoms, or 4) unwanted or uncontrollable side effects related to the medication. 4. participants must have normal or corrected-to-normal vision in order to complete the cognitive task. exclusion criteria: the following exclusion criteria exist for all participants: 1. lack of consent. 2. participants cannot have started a new treatment within the last 30 days. 3. participants cannot have a history of hydrocephalus, autism spectrum disorder, schizophrenia, conduct disorder, oppositional defiant disorder, active substance abuse, or be on a beta blocker. 4. participants cannot have previously used the apollo system.

Keywords: adhd inhibition vibrational therapy
management and thermal comfort of premature infants under 32 weeks

Conditions: Thermoregulation

Summary: sleep propensity was assessed in terms of the duration of a spontaneous episode of wakefulness (w). skin temperatures at six body sites (the abdomen, pectoral region, eye, hand, thigh and foot) were measured (using infrared thermography) during nocturnal polysomnography in 29 9-day-old preterm neonates (postmenstrual age: 209 9 days). te investigators then determined whether the duration of the w episode depended upon the local skin temperatures measured at the start, during and end of the episode.

although sleep is of paramount importance for preterm neonates, care of the latter in a neonatal intensive care unit does not favour sleep. given that several studies in adults have described a 'vegetative preparedness to sleep' (in which distal skin vasodilation before lights-out promotes rapid sleep onset), the investigators looked at whether or not this process operates in preterm neonates. sleep propensity was assessed in terms of the duration of a spontaneous episode of wakefulness (w). skin temperatures at six body sites (the abdomen, pectoral region, eye, hand, thigh and foot) were measured (using infrared thermography) during nocturnal polysomnography in 29 9-day-old preterm neonates (postmenstrual age: 209 9 days).

Eligibility criteria:
inclusion criteria: * premature newborns 25 to 32 weeks of amenorrhea; * arrival in the neonatal medicine unit \<12 hours of life; * need for management in a closed incubator; * availability of an incubator equipped with communication card. exclusion criteria: * premature newborns\> 32 weeks of amenorrhea; * arrival in the neonatal medicine unit after 12 hours of life; * presence of malformation syndrome or serious heart disease; * pathology requiring management within the first 10 days of life; * apgar score \<5 at 10 minutes of life; * need for initial management in an open incubator; * unavailability of an incubator equipped with a communication card

Keywords: infant thermoregulation wakefulness episode
a study to compare the efficacy of alendronate with and without calcium or calcium alone in the treatment of osteoporosis in postmenopausal women (0217-088)(completed)

Conditions: Osteoporosis, Postmenopausal

Summary: the purpose of this study is to see how well alendronate and calcium as compared to calcium alone increase bone density in postmenopausal women with osteoporosis


Eligibility criteria:
inclusion criteria : * patient is postmenopausal (or surgically menopausal) for at least 5 years. * patient must be diagnosed with osteoporosis * patient has spinal anatomy suitable for dexa of the lumbar spine exclusion criteria : * patient is receiving or has received treatment prior to randomization which might influence bone turnover * patient has a history of or evidence for metabolic bone disease (other than postmenopausal bone loss) * patient is receiving or is expected to receive during the course of the study any medication (other than study medication) which might alter bone or calcium metabolism
patient satisfaction with propofol for out patient colonoscopy

Conditions: Colon Cancer; IBS; Polyps

Summary: the primary purpose of this study is to determine if patient satisfaction with propofol is better than with non-propofol anesthesia for outpatient colonoscopies.

outpatient colonoscopies are very common, indicated for various reasons, and are more commonly performed in outpatient surgery or endoscopy centers. there is an increase in the use of propofol for sedation because of the short duration of action and quick turn around time. propofol has been studied extensively for safety and efficacy but patient satisfaction and preference with use has not been well documented in prospective, randomized setting. in the context of the recent changes in healthcare reimbursement where patient satisfaction is becoming an important metric providing data that could improve patient satisfaction is needed. patients who presented for a colonoscopy with the principal investigator were approached to participate in the study. after obtaining consent the patients were randomized to anesthesia with propofol or control without propofol per random number tables provided by the statistician. the anesthesiologist or nurse anesthetist were asked to remove the paper with the assignment from the envelope to determine which medications to give the patient. pre-op, intra-op, and post-op data were collected by registered nurses blinded to the anesthetic. the day one follow-up phone call was made by the resident who was blinded to the anesthetic. data were collected in the pre-op, intra-op, and post-op areas by the researchers who were blinded to the medications used.

Eligibility criteria:
inclusion criteria: - patients having an outpatient colonoscopy exclusion criteria: - high risk patients (asa iv \& v) who are not candidates for colonoscopy in an outpatient center will be excluded.

Keywords: propofol colonoscopy patient satisfaction
cryoballoon pulmonary vein isolation: time-to-isolation dependent freeze protocols comparison

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to develop and prospectively test two cryo-af (atrial fibrillation) dosing protocols guided exclusively by time-to-isolation (tt-i) in patients undergoing a first-time cryo-af. both protocols guided by tt-i are associated with shorter cryoapplications as compared to conventional approach. in the first group freeze duration is tti +120 s. in the second group freeze duration is 240s if tti is \ 75s a 240s bonus freeze is applied. the investigators examine long-term efficacy of cryo-af using the two proposed dosing algorithms in a nonrandomized fashion. the study cohort consists of consecutive patients undergoing a first-time cryo-af for symptomatic paroxysmal or persistent af (atrial fibrillation) at interventional cadiology and cardiac arrhythmias clinic of medical university in łódź. during 12 months investigators are planning to enroll 40 patients patients are randomly assigned to the groups. all of them will be followed up 3 and 12 months after the procedure. in addition, ambulatory electrocardiographic monitoring will also be performed at 3 and 12 months. the study is requested for an approval of the university ethics committee.


Eligibility criteria:
inclusion criteria: diagnosis of paroxysmal or persistent atrial fibrillation on electrocardiogram exclusion criteria: diagnosis of sinus rhythm on electrocardiogram

Keywords: atrial fibrillation
ketogenic diet effects on the frequency of non epileptic seizures

Conditions: Non Epileptic Seizures; Functional Neurological Symptom Disorder; Conversion Disorder; Ketogenic Dieting

Summary: the objective of this study is to determine the effects of the ketogenic diet on the frequency of non-epileptic seizures in patients with functional neurological symptoms disorder compared to a healthy diet.

this study consists of a open label randomized controlled clinical trial comprised of 20 patients with diagnosis of functional neurological symptom disorder with non epileptic seizures distributed in 2 arms of 10 patients each. patients will be randomly assigned to one of the groups. both groups will be receiving treatment as usual (ssri and/or psychotherapy). one group will be assigned a ketogenic diet while the other will be assigned a healthy diet, both supervised by a team of nutritionists. patients will be evaluated every 2 weeks until reaching 6 weeks.

Eligibility criteria:
inclusion criteria: * patients who have a record at the institute and who have a diagnosis of a dissociative neurological symptom disorder with non-epileptic seizures with a certainty of at least clinically established who have a monthly seizure frequency greater than 3. * patients with the characteristics described above with comorbid epilepsy but who have not presented epileptic seizures in the last month. * patients with the aforementioned characteristics and who give their informed consent in writing to participate in the study. * patients who, once the diet has been explained to them, consider it feasible to implement it at least for the follow-up time. exclusion criteria: * patients with metabolic or hemodynamic instability, liver failure, inability to tolerate the oral route, acute pancreatitis or pregnancy due to the possible teratogenic effect that has not yet been elucidated. * patients with metabolic disorders such as primary carnitine deficiency, palmitoyltransferase carnitine i or ii deficiency, carnitine translocase deficiency, beta oxidation defects, pyruvate carboxylase deficiency, porphyria and other fatty acid transport and oxidation disorders.
the impact of functional exercise training on postoperative knee joint recovery in patients with meniscal injury

Conditions: Functional Exercise Training; Knee Meniscus Injury; Knee Joint Function

Summary: aim: to investigate the impact of functional exercise training on postoperative functional recovery in patients with knee meniscus injuries. methods:a prospective randomized controlled trial (rct) was conducted from april 2023 to september 2024, involving 96 patients with knee meniscus injuries who underwent meniscus repair interventions. participants were randomly assigned to either the control （con） group (n=48) or the functional exercise training (fet) group (n=48) using a computer-generated random number table. the con group received standard rehabilitation, while the fet group underwent functional exercise training. clinical outcomes were evaluated at baseline, 1 month, and 6 months post-intervention, including the lysholm score, ikdc score, vas pain score, range of motion (rom), serum levels of prostaglandin e2 (pge2) and serotonin (5-ht), as well as passive 60° position sense and 60° motion sense. postoperative complications occurring within 1 month were also recorded.


Eligibility criteria:
inclusion criteria: * meniscus injury was diagnosed by magnetic resonance imaging; meniscoplasty was performed; no shedding occurred during follow-up. exclusion criteria: * patients with joint dislocation and fracture; poor compliance; severe osteoarthritis, rheumatoid arthritis; combined with metabolic diseases, coagulation disorders and serious organic diseases.

Keywords: functional exercise training knee meniscus injury knee joint function
a study of cusatuzumab in combination with azacitidine compared with azacitidine alone in patients with higher-risk myelodysplastic syndrome (mds) or chronic myelomonocytic leukemia (cmml) and who are not candidates for hematopoietic stem cell transplantation (hsct)

Conditions: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic

Summary: the purpose of the study is to compare overall response rate (orr) between treatment groups in participants with higher-risk myelodysplastic syndrome (mds) or chronic myelomonocytic leukemia (cmml) who are not eligible for hematopoietic stem cell transplantation (hsct).

cusatuzumab (also known as jnj-74494550 and argx-110) is a humanized monoclonal antibody of camelid origin that binds with high affinity to human cluster of differentiation 70 (cd70). azacitidine (an hypomethylating agent \[hma\]) is approved for the treatment of higher-risk mds in the united states (us) and the european union (eu). both approvals are based on data showing decreased transfusion burden, delayed progression to acute myeloid leukemia (aml), improved quality of life, and extended survival. it is hypothesized that the addition of cusatuzumab to azacitidine will result in an improvement in overall response rate (orr) compared with azacitidine alone in participants with higher-risk mds or cmml.

Eligibility criteria:
inclusion criteria: * diagnosis of de novo or secondary higher-risk myelodysplastic syndrome (mds) or chronic myelomonocytic leukemia (cmml) per world health organization (who) 2016 criteria * at study entry, higher-risk mds (intermediate, high, and very high risk mds per revised international prognostic scoring system \[ipss r\]) or higher-risk cmml (intermediate-2 or high risk cmml per cmml-specific prognostic scoring system \[cpss-mol\]). participants with previous lower-risk mds or cmml that has evolved to higher-risk mds or cmml are eligible * at study entry, not a candidate for hematopoietic stem cell transplantation (hsct) * eastern cooperative oncology group (ecog) performance status score of 0, 1, or 2 * adequate liver and renal function defined as follows: aspartate aminotransferase (ast) or alanine aminotransferase (alt) less than (\ ) 30 milliliter per minute per 1.73 square meters (ml/min/1.73 m\^2) (by modification of diet in renal disease formula) exclusion criteria: * received prior hsct or any prior treatment, including hypomethylating agent (hmas), for higher-risk mds or cmml. prior supportive therapies including transfusion and growth factors are acceptable * received prior treatment with cusatuzumab * presence of the breakpoint cluster region protein-abelson murine leukemia (bcr-abl) rearrangement * received a live, attenuated vaccine within 4 weeks prior to initiation of study drug * any active systemic infection
epirubicin and docetaxel combination (et) or epirubicin followed by docetaxel (e/t) for node negative (n0) high risk breast cancer patients

Conditions: Breast Cancer

Summary: the combination of taxanes, and especially docetaxel, with an anthracycline seems to be an important part of the chemotherapy regimens used in the adjuvant setting of patients with early-stage node-positive breast cancer patients. whether sequential or concurrent administration of these drugs is preferable is not yet known, especially in patients with node-negative high risk tumors.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed breast adenocarcinoma. * within 20-45 days after the surgical excision of the primary tumor with tumor-free operation margins; at least 10 axillary lymph nodes have to be removed. * absence of lymph node involvement after eclosion and hormone (e\&h) staining and light microscopy evaluation. * premenopausal or postmenopausal women with at least one of the following tumor characteristics is required in order to characterize the tumor as high risk: * estrogen receptor (er) (-) and progesterone receptor (pr)(-); * ki-67 + \> 30%; grade iii; her2 (3+) (after an amendment on 15.05.2008 women with her2 (3+) were not included); perineural infiltration or presence of tumor emboli in blood or lymph vessels. * postmenopausal women with tumors 1-2 cm are eligible if the tumor has at least 2 of the above mentioned high risk criteria. * premenopausal and postmenopausal women with tumors measuring \> 2 cm are eligible irrespectively of the expression of the above adverse prognostic tumor criteria. * absence of any clinical or radiological evidence of local or metastatic disease. * age \> 18 years. * performance status (who) \< 3. * adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3). * adequate liver (bilirubin \< 1.5 times upper limit of normal and sgot/sgpt \< 2 times upper limit of normal) and renal function (creatinine \< 2 mg/dl). * adequate cardiac function (lvef \> 50%). * negative pregnancy test. * informed consent. exclusion criteria: * other invasive malignancy within the past 5 years except nonmelanoma skin cancer. * other concurrent uncontrolled illness that could affect compliance with the study. * psychiatric illness or social situation that would preclude study compliance. * pregnant or nursing women. * history of allergic reaction attributed to docetaxel. * other concurrent investigational agents.

Keywords: high risk node negative
effect of esketamine on anxiety state in patients undergoing abdominal tumor surgery

Conditions: Anxiety State; Esketamine

Summary: to evaluate whether esketamine can relieve anxiety in patients undergoing abdominal tumor surgery.

hamilton anxiety scale was used to screen patients with anxiety. only patients with score ≥ 8 were enrolled. these patients were randomly assigned to the experimental group and control group. all patients enrolled were evaluated with hamilton anxiety scale, phq-8 scale, qor-15 scale and athens insomnia scale. after induction, sevoflurane and remifentanil were used to maintain anesthesia. the experimental group had esketamine while the control group had normal saline. athens insomnia scale was used to assess the sleep status 1, 2, 3 days after surgery and 1 month after surgery. hamilton anxiety scale was used to evaluate the anxiety state of the patients 3 days after surgery and 1 month after surgery. phq-8 scale, qor-15 scale were collected 3 days after surgery and 1 month after surgery.

Eligibility criteria:
inclusion criteria: * patients undergoing abdominal tumor surgery; * older than 18 years old and younger than 70 years old; * asa grade i-iii； * hamilton anxiety scale ≥ 8. exclusion criteria: * having serious mental illness before surgery or on antipsychotic medication in the two weeks before screening; * severe organ function lesions such as heart failure (left ventricular ejection fraction \<30%), myocardial infarction, kidney failure (requiring kidney replacement therapy), liver function impairment (child-pugh grade c), etc. * patients arranged to receive general anesthesia combined with epidural anesthesia patients; * patients who cannot communicate, read or write due to visual, auditory, language or other reasons; * patients allergic to ketamine; * patients refused to use postoperative self-controlled intravenous analgesia pump; * patients refused to participate in the study.

Keywords: esketamine anxiety state